Apricus Biosciences, Inc.: Apricus Biosciences Announces National Phase Approval for Erectile Dysfunction Cream - Vitaros(R) in

   Apricus Biosciences, Inc.: Apricus Biosciences Announces National Phase
       Approval for Erectile Dysfunction Cream - Vitaros(R) in Belgium

Vitaros(R) Remains on Track for Launch in 2014

 SAN DIEGO, Jan. 23, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
 ("Apricus" or the "Company") (Nasdaq:APRI) (www.apricusbio.com), today
 announced that Belgium's Ministry of Social Affairs, Public Health and
 Environment has granted national phase approval to Vitaros^®, indicated for
 the treatment of patients with erectile dysfunction ("ED"). The Company has
 now received a total of eight national phase approvals for Vitaros^®,
 including Belgium, France, Germany, Ireland, Italy, the Netherlands, Sweden
 and the United Kingdom ("UK") following its broad approval by European
 health authorities in June 2013. Apricus has an exclusive commercialization
 partnership in place with Hexal AG, an affiliate within the Sandoz Division
 of the Novartis Group of Companies ("Sandoz"), for the commercialization of
 Vitaros^® in several European countries, including Belgium.

 "We are pleased to be working with our partner Sandoz as they make progress
 towards preparing Vitaros^® for commercial launch in their licensed
 territories including Belgium," said Richard Pascoe, Chief Executive Officer
 of Apricus."We remain excited about the opportunity for all of our existing
 partners to bring the first and only on-demand, topical erectile dysfunction
 treatment to the market this year."

 In June 2013, Apricus announced that its marketing application for Vitaros^®
 was approved through the European Decentralized Procedure ("DCP").Under the
 DCP, Apricus filed its application for marketing approval designating the
 Netherlands as the Reference Member State ("RMS") on behalf of nine other
 European Concerned Member States ("CMS") participating in the procedure.The
 Company continues to work toward obtaining the remaining national phase
 approvals in Spain and Luxembourg. 

 Once launched, Vitaros^® will become the first new and novel ED product in
 nearly a decade, and with its unique product profile that addresses a large
 number of patients who cannot or do not respond well to the existing
 therapies, or who are intolerant to the systemic effects of PDE-5
 inhibitors, it is well-positioned for commercial success.In Europe alone,
 the existing ED products generated over $1 billion in sales in 2012.Apricus
 believes that a significant portion of the market remains untreated or
 under-treated, which represents a substantial commercial opportunity for
 Vitaros^®.

 Vitaros^® is currently partnered in key markets, including with Takeda in
 the UK, Sandoz in Germany, Switzerland and certain countries in Northern
 Europe, Bracco in Italy, Majorelle in France, Monaco and certain African
 countries, and Abbott in Canada.The Company's existing commercialization
 partners are preparing for Vitaros^® product launches in their respective
 territories with product launches expected throughout 2014. 

 About Vitaros^®

 Vitaros^® has been approved for the treatment of ED by the European health
 authorities and by Health Canada. Vitaros^® is a topically-applied cream
 formulation of alprostadil, a vasodilator, combined with our proprietary
 permeation enhancer DDAIP.HCl, which directly increases blood flow to the
 penis, causing an erection.Alprostadil is a widely accepted alternative to
 the PDE-5 inhibitors for difficult to treat patients, and Vitaros^®, which
 was determined to be safe and effective by the European health authorities
 and previously by Health Canada, offers greater market opportunity due to
 its patient-friendly form versus other alprostadil dosage forms and also
 relative to oral ED products.With nearly 150 million men worldwide who
 suffer from ED and an ED market size of approximately $1 billion in revenue
 in Europe alone, Vitaros^® represents a major market opportunity for Apricus
 and its commercial partners given its unique product profile and its
 potential to treat a large underserved population.

 About Apricus Biosciences, Inc.

 Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops
 and markets through its licensing partners innovative treatments that have
 the potential to help large patient populations across numerous,
 large-market therapeutic classes including male and female sexual
 health.The Company has one approved product, Vitaros^®, for the treatment
 of erectile dysfunction, which is now approved in Europe and Canada and will
 be commercialized by Apricus' marketing partners, which include Abbott
 Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG
 (Sandoz), Bracco SpA and Laboratoires Majorelle.Femprox^®, the Company's
 product candidate for the treatment of female sexual interest/arousal
 disorder, has successfully completed a nearly 400-subject proof-of-concept
 study.

 For further information on Apricus, visit http://www.apricusbio.com.

 Apricus' Forward-Looking Statement Safe Harbor

 Statements under the Private Securities Litigation Reform Act, as amended:
 with the exception of the historical information contained in this release,
 the matters described herein contain forward-looking statements that involve
 risks and uncertainties that may individually or mutually impact the matters
 herein described for a variety of reasons that are outside the control of
 the Company, including, but not limited to, its ability to further develop
 its product Vitaros^® for ED, such as the room temperature version of
 Vitaros^® and product candidate Femprox^® for female sexual interest/arousal
 disorder among others; to have its product and product candidates receive
 additional patent protection and be approved by relevant regulatory
 authorities in Europe, the United States, Canada and in other countries,
 such as additional national phase approvals for Vitaros^® in the remaining
 CMS territories, Spain and Luxembourg; to successfully commercialize such
 product and product candidates and other NexACT® product candidates and drug
 delivery technology; and to achieve its other development, commercialization
 and financial goals, such as successfully manufacturing and launching
 Vitaros^® in partnered territories. Readers are cautioned not to place undue
 reliance on these forward-looking statements as actual results could differ
 materially from the forward-looking statements contained herein. Readers are
 urged to read the risk factors set forth in the Company's most recent annual
 report on Form 10-K, as amended, subsequent quarterly reports filed on Form
 10-Q, as amended, and other filings made with the SEC. Copies of these
 reports are available from the SEC's website or without charge from the
 Company.

CONTACT: Apricus Investor Relations:
        
         David Pitts or Lourdes Catala
         Argot Partners
         212-600-1902
         david@argotpartners.com
         lourdes@argotpartners.com

------------------------------------------------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf
of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for
the content, accuracy and originality of the information contained therein.
Source: Apricus Biosciences, Inc. via Globenewswire
HUG#1756761
 
Press spacebar to pause and continue. Press esc to stop.